Anavex Life Sciences Corp (AVXL)

[Gator328]

It's 2015. You're the CEO of a small biotech with a promising new drug that just aced its P1 safety trial, and has about a month of data showing the potential for efficacy. You have a long and arduous road to figure out trial designs and dosages and method of drug delivery, etc.

Who would you rather have on your Board: Elliot Favus or Jiong Ma?

It's 2021. Your P3 trial design has been approved and is nearly fully enrolled. You have years of data indicating the drug is safe and effective. The FDA's only remaining major role is to approve or reject based on the trial results.

If A273 is effective, there will undoubtedly be interest from larger firms interested in a partnership or acquisition. The other option is to try and grow Anavex into something much larger and eventually try to become a major player in the sector.

Now who would you rather have on your Board of Directors:

Elliot Favus or Jiong Ma.

She brings value to Anavex at this stage in its growth cycle, just as Dr. Favus brought value when Anavex had a more urgent need to understand how the FDA operates.

How much value remains to be seen...

(P.S. -- the energy sector is full of mergers and acquisitions)